GlassScriptPhysician profile
Anjali Dutta
NPI 1063850949
$2,781.36
in general payments reported to CMS, 2019-2025
21 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $15.80 · 2021: $55.45 · 2022: $269 · 2023: $672 · 2024: $959 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $893.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $394.95 | 2024-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Amgen INC. | $221.61 | 2022-2025 | Repatha, Repatha, Evenity |
| Pfizer INC. | $177.85 | 2023-2025 | |
| Astellas Pharma US INC | $148.65 | 2019 | |
| Novo Nordisk INC | $142.11 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $130.50 | 2022-2024 | Farxiga |
| Baxter Healthcare | $103.70 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $103.15 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.82 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $83.91 | 2022-2023 | Verquvo |
| Lantheus Medical Imaging, INC. | $51.77 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.35 | 2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $34.46 | 2021-2022 | |
| Abbott Laboratories | $34.41 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.34 | 2024 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $22.89 | 2023 | Zio Xt Patch |
| Optinose US, INC. | $20.41 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.90 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $14.19 | 2022 | |
| Medtronic Vascular, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Dutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.